The impact of oxidative stress in human cancer has been extensively studied. It is accepted that elevated reactive oxygen species (ROS) promote mutagenic DNA damage. Even with an extensive armament of cellular antioxidants and detoxification enzymes, alterations to DNA occur that initiate cellular transformation. Erythroid 2p45 (NF-E2)-related factor 2 (Nrf2) is a basic-region leucine zipper transcription factor that mediates the expression of key protective enzymes through the antioxidant-response element (ARE). By analysing 10 human prostate cancer microarray data sets, we have determined that Nrf2 and members of the glutathione-S-transferase (GST) mu family are extensively decreased in human prostate cancer. Using the TRAMP transgene and Rb and Nrf2 knockout murine models, we demonstrated that the loss of Nrf2 initiates a detrimental cascade of reduced GST expression, elevated ROS levels and ultimately DNA damage associated with tumorigenesis. Based on overwhelming data from clinical samples and the current functional analysis, we propose that the disruption of the Nrf2-antioxidant axis leads to increased oxidative stress and DNA damage in the initiation of cellular transformation in the prostate gland.
Introduction
The role of oxidative damage and reactive oxygen species (ROS) has been studied in many cancers (Guyton and Kensler, 1993) . ROS originate from both endogenous and exogenous sources and are produced during normal cellular respiration. Exogenous sources include various carcinogens such as estrogenic compounds, redox cycling compounds, metals (through the Fenton reaction), radiation and chemotherapeutic agents. These sources produce a variety of ROS, which include hydrogen peroxide, the hydroxyl radical, the hydroperoxyl radical and the superoxide anion (Klaunig and Kamendulis, 2004) . Through the use of antioxidants, cells are able to neutralize ROS under normal physiologic conditions. These antioxidants include enzymes, such as superoxide dismutase, catalase, glutathione peroxidase and thioredoxin, or non-enzymatic compounds such as Vitamin E, Vitamin C and glutathione. Studies have shown that antioxidant enzymes including superoxide dismutase, catalase and several classes of glutathione-S-transferase (GST) are downregulated in human prostate cancer (Baker et al., 1997; Bostwick et al., 2000 Bostwick et al., , 2007 .
Erythroid 2p45 (NF-E2)-related factor 2 (Nrf2) is a basic-region leucine zipper (bZIP) transcription factor that, along with small Maf proteins, has been demonstrated to mediate gene expression through the antioxidant-response element (ARE) (Hayes and Pulford, 1995; Venugopal and Jaiswal, 1996; Itoh et al., 1997; Zhu and Fahl, 2001 ). The ARE is a promoter-enhancer element, which in response to ROS, carcinogens, antibiotics and xenobiotics, regulates the basal transcription and induction of antioxidant enzymes (Dhakshinamoorthy et al., 2000; Jaiswal, 2000) . Examination of several GST and other antioxidant enzyme promoter regions in mouse, rat and humans indicates that the ARE is conserved in multiple species (Hayes et al., 2004) . The Nrf2 protein is regulated by Keap1 (Kelchlike ECH-associated protein 1), which binds to and sequesters Nrf2 in the cytoplasm. (Itoh et al., 1999) . Thiol modification by ROS of one or more of the cysteines in Keap1 induces a conformational change, which then releases Nrf2 for translocation to the nucleus (Kwak et al., 2004) .
Nrf2 has been shown to regulate antioxidants such as NAD(P)H:quinone oxidoreductase (NQO1), heme oxygenase, thioredoxin reductase 1, glutamate-cysteine ligase modifier subunit and glutamate-cysteine ligase catalytic subunit (Kwak et al., 2003; Lee et al., 2003b) . It has also been demonstrated in Nrf2 knockout mice that various GST family members, including alpha and mu, are downregulated in liver (Chanas et al., 2002) and total GST activity is decreased by 30-70% in the intestine (Ramos-Gomez et al., 2001) . Theses studies indicate that Nrf2 regulates expression of ROS detoxification enzymes in response to the redox state of the cell. In this capacity, Nrf2 may impact chemopreventive efficacy and sensitivity to carcinogenesis in bladder (Iida et al., 2004) , stomach (Ramos-Gomez et al., 2001 ) and liver in mouse.
In the cell, when either ROS levels are increased or antioxidant levels are decreased, ROS can damage lipids, proteins and DNA. Recently, studies have demonstrated that increased oxidative damage correlates with tumor progression in two different mouse models of prostate tumorigenesis. Ouyang et al. (2005) have shown that DNA and protein are increasingly damaged by oxidation during tumor progression in Nkx3.1À/À and Nkx3.1À/À PtenÀ/À mice. Additionally, Tam et al. (2006) demonstrated similar results in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate carcinoma, where increased oxidative and nitrosative damage was exhibited in the prostate gland during tumorigenesis.
TRAMP is a highly penetrant model of prostate cancer, in which SV40 TAg and tAg are expressed under the control of the prostate epithelial cell-specific rat probasin promoter (Greenberg et al., 1995) . Expression of these antigens results in loss of function of the three pocket proteins (retinoblastoma protein (pRb), p107 and p130) and p53. Inhibition of these proteins leads to spontaneous development of prostate cancer from normal prostate beginning at 6 weeks of age concurrent with the onset of transgene expression resulting in hyperplasia, adenocarcinoma, metastasis and eventually death (Greenberg et al., 1995) .
Considering the critical role Nrf2 plays in cellular detoxification and ROS regulation, we analysed Nrf2 expression in human prostate cancer gene profiling studies and two murine models of prostate tumorigenesis. Based on the current study, we conclude that Nrf2 is downregulated in human prostate cancer and that, functionally, the loss of Nrf2 results in a cascade of events, that is, reduced expression and reduced activity of GST enzymes, increased levels of ROS and increased DNA damage. These results indicate the loss of Nrf2 results in DNA damage that may promote prostate tumorigenesis.
Results
Nrf2 and GSTs are downregulated in human prostate cancer Considering that Nrf2 regulates detoxification proteins in response to increased ROS levels, a mechanism that is often disrupted in cancer, we initiated the first comprehensive analysis of Nrf2 levels in human prostate cancer. Nrf2 and several of its GST mu targets were analysed using the Oncomine bioinformatics tool (www.oncomine.org). This website utilizes published human cancer gene expression data sets to provide individual gene analysis of the data as well as meta-analysis of groups of studies (Rhodes et al., 2004) . In 10 studies (Dhanasekaran et al., 2001; Luo et al., 2001; Magee et al., 2001; Welsh et al., 2001; LaTulippe et al., 2002; Glinsky et al., 2004; Lapointe et al., 2004; Yu et al., 2004; Varambally et al., 2005; Vanaja et al., 2006) in which prostate tumor samples were compared to benign prostate tissue, Nrf2 was significantly decreased (Po0.05) in all studies (Table 1) . A detailed box plot of Nrf2 expression from the Lapointe study (Lapointe et al., 2004 ) is shown in Figure 1 along with expression data for GST mu 1, 3 and 5. These results from human data sets suggest that Nrf2 and several of its target genes are significantly downregulated in human prostate cancer and continue to decrease during progression to metastatic disease.
Nrf2 and GSTs are downregulated in the TRAMP mouse model Tam et al. (2006) have demonstrated that the TRAMP model of prostate cancer exhibits increased oxidative damage. Based on this observation, we decided to use TRAMP as a model of oxidative damage during prostate tumorigenesis. We examined the expression of Nrf2 and GST mu isoforms, regulated by Nrf2, at the mRNA, protein and measured enzymatic activity levels in normal prostate and at various stages of prostate tumor progression in the TRAMP model. Nrf2, GST mu1, GST mu2 (the murine ortholog of human GST mu3) and GST mu 5 mRNA levels were analysed by reverse transcription-polymerase chain reaction (RT-PCR) and found to be decreased in localized prostate cancer when compared to normal prostate (Figure 2a ). Densitometric quantitation reveal statistically significant differences for all four genes (Figure 2b ).
Western blot analysis was performed on multiple animals to determine if lower Nrf2 mRNA levels correlated to decreased protein levels. Indeed, Nrf2 protein is downregulated in poorly differentiated prostate tumors and lymph node metastases as compared to normal tissue (Figure 2c ). It is interesting to note that partial repression of Nrf2 correlates with the moderate level of TAg expression in earlier stage prostatic intraepithelial neoplasia (PIN). We have concluded that several GST mu family members are decreased at the mRNA level, however, other GSTs may be upregulated to compensate for the loss of their activity. To determine if total GST enzymatic activity is reduced in TRAMP tissues, GST enzyme assays were performed on wildtype, PIN, poorly differentiated localized prostate cancer and lymph node metastases ( Figure 2d ). The results reveal a direct correlation between reduced Nrf2 and GST mu mRNA levels, and decreased enzymatic activity. The premalignant PIN samples exhibited similar GST activity as normal prostate, but both poorly differentiated prostate cancer and lymph node metastases revealed markedly decreased GST activity ( Figure 2d ).
Nrf2 transcriptional activity is attenuated in RbÀ/À cells
The Rb tumor suppressor is prominently inhibited in the TRAMP model of murine prostate cancer. We have previously shown that the specific loss of Rb, by prostate tissue recombination, results in RbÀ/À prostate grafts that are hypersensitive to hormone induced carcinoma (Wang et al. 2000) . To investigate the specific link between Rb loss and Nrf2 repression, we examined Nrf2 mRNA and protein levels in wild type (Rb þ / þ ) and Rb knockout (RbÀ/À) murine prostate epithelial cell lines and found substantially decreased Nrf2 levels in the absence of Rb (Figure 3a ). This finding was reproducible in multiple Rb þ / þ and RbÀ/À prostate epithelial cell lines. This finding suggested an attenuation in the antioxidant response of RbÀ/À cells to hormone-induced DNA damage and carcinogenesis. Although Nrf2 mRNA and protein levels are decreased in RbÀ/À cells, there is still a possibility that minimal levels can activate Nrf2 target genes. We utilized a luciferase reporter driven by a Nrf2-sensitive hNQO1-ARE promoter to determine endogenous, as well as, inducible Nrf2 transcription activity in Rb þ / þ and RbÀ/À prostate epithelial cells. Consistent with reduced Nrf2 expression in RbÀ/À cells, endogenous NQO1-ARE promoter activity was approximately four times greater in Rb þ / þ than in RbÀ/À cells. Furthermore, when treated with tBHQ, a Nrf2 activator, a dose-dependent increase in reporter expression was observed in Rb þ / þ cells, whereas RbÀ/À cells showed no detectable increase in NQO1-ARE reporter Figure 1 Nrf2 and GST mu expression in human prostate cancer. A representative box plot of Nrf2 and three GST mu isoforms from Lapointe et al., 2004 . Ten prostate cancer gene expression studies were analysed using Oncomine (http://www.oncomine.com) and indicate that Nrf2 is significantly downregulated at the mRNA level in localized and metastatic prostate tumor compared to normal prostate (Table 1) . GST, glutathione-S-transferase.
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GST mRNA and enzymatic activity are decreased in RbÀ/À and Nrf2À/À prostate epithelial cells Because Nrf2 expression and ARE activation are decreased in RbÀ/À cells, we examined the expression of GST mu isoforms 1, 2 and 5 in the same model. Using a cDNA microarray that compared Rb þ / þ and RbÀ/À cells (McCabe et al., 2005a, b) , we found that the specific loss of Rb induced an average 3.14-fold downregulation of GST mu 1, 2 and 5 cDNA, which was validated by RT-PCR (Figure 4a ). To determine if decreased GST expression translated to lower enzymatic activity, whole cell lysates were obtained from Rb þ / þ (normal Nrf2 levels) and RbÀ/À cells (decreased Nrf2 levels) and GST enzymatic activity was measured as described in Materials and methods. As suggested by Nrf2 and GST expression data, RbÀ/À cell lines showed a significant decrease in GST activity when compared to Rb þ / þ cells (Figure 4b ). In an effort to determine if other antioxidant enzymes are downregulated, we examined both subunits of glutamate-cysteine ligase (glutamate-cysteine ligase catalytic subunit and glutamate-cysteine ligase modifier subunit) and thioredoxin reductase 1 by RT-PCR and did not find them to be differentially regulated in Rb þ / þ compared to RbÀ/À cells. pRb is responsible for the regulation of many cell cycle events and it is possible that the decreased GST expression, seen in TRAMP and RbÀ/À cells is not specifically due to decreased Nrf2 activity in these models. To address specificity, we investigated the contribution of Nrf2 directly to DNA damage by ROS by establishing multiple prostate epithelial cell lines from Nrf2À/À mice (Nrf2À/À cells) (Chan et al., 1996) . We then examined GST mu 1, 2 and 5 expression by semi-quantitative PCR, which showed that these GST isoforms are transcriptionally decreased in the absence of Nrf2 (Figure 4c ). This finding was reproducible in multiple Nrf2 þ / þ and Nrf2À/À cell lines.
In addition, whole cell lysates were obtained from Nrf2 þ / þ and Nrf2À/À cells and GST activity was measured as described above. As correlated with the Nrf2 and GST expression data, Nrf2À/À cell lines showed a threefold decrease in GST activity when compared to Nrf2 þ / þ cells (Figure 4d ).
Loss of Nrf2 increases ROS levels
To determine whether decreased Nrf2 expression resulted in increased ROS levels we employed 2 0 ,7 0 -dichlorofluorescin diacetate (DCFDA) flourescence to measure the ROS levels under normal cell culture conditions. DCFDA is sensitive to oxidation by ONOO, H 2 O 2 (in combination with cellular peroxidases), peroxidases alone and Á OH (Myhre et al., 2003) . The results ( Figure 5A ) indicate that under normal culture conditions Nrf2-deficient RbÀ/À cells have significantly increased ROS levels (DCFDA) higher than Rb þ / þ cells exhibiting normal Nrf2 levels and activity.
As previous studies have shown that Nrf2À/À cell lines have decreased levels of antioxidant and detoxification enzymes in various tissues (Itoh et al., 1997; Jaiswal, 2000; Ramos-Gomez et al., 2001) , we wanted to measure ROS levels in Nrf2À/À cells. We repeated the DCFDA assay to measure the ROS levels under normal cell culture conditions. As shown in Figure 5B , results demonstrate that under normal culture conditions Nrf2À/À cells also have significantly increased ROS levels over Nrf2 þ / þ cells.
Loss of Nrf2 increases DNA damage
To determine whether decreased antioxidant response resulting from decreased Nrf2 levels promoted DNA damage, we assessed the prevalence of single/double strand DNA breaks in Nrf2 deficient cells by single cell gel electrophoresis (Comet Assay). Increased DNA distribution of 1.5-fold was seen in the Nrf2-deficient RbÀ/À over Rb þ / þ cells. (Figure 5C ). These results indicate that ROS-induced DNA damage occurs in Nrf2-deficient cells under normal cell conditions due to an attenuated response to oxidative stress.
To determine whether the DNA damage seen in RbÀ/À cells is due to decreased antioxidant response because of diminished Nrf2 levels, we again used the Comet Assay. DNA damage was assessed in untreated Nrf2 þ / þ and Nrf2À/À cells and we found a twofold increase in fragmented DNA in the Nrf2À/À cells ( Figure 5C ). This result indicated that increased ROS-induced DNA damage observed in RbÀ/À cells is due to decreased Nrf2 expression in RbÀ/À cells.
Discussion
Nrf2 is a transcription factor that is activated by increased ROS, which induces the transcription of several antioxidant and detoxification enzymes including several classes of GST (Kwak et al., 2003; Lee et al., 2003b) . Previous reports have demonstrated increased oxidative damage in PIN and primary prostate tumors in mouse (Ouyang et al., 2005; Tam et al., 2006) . Additionally, a recent report by Bostwick et al. (2007) showed that several classes of GSTs are downregulated with tumor progression in the prostate. Much of the current emphasis of Nrf2 research in cancer, rightly, has been focused on utilizing this pathway in a chemopreventive manner (reviewed in Yu and Kensler (2005) ). The current study, which is the first to demonstrate that Nrf2 is downregulated in human prostate cancer, the TRAMP mouse and cell lines from a hormone-inducible model of RbÀ/À prostate cancer, indicates that maintaining normal Nrf2 expression and activity may be important in chemopreventative strategies for prostate cancer.
We used the Oncomine database to examine Nrf2 levels across published human cDNA prostate. We found significantly reduced Nrf2 levels in tumor compared to normal prostate in 10 studies. In addition, two other Nrf2 regulated genes (NQO1 and glutamatecysteine ligase catalytic subunit) were shown to be downregulated in these studies (data not shown). Our data also agree with the findings of Brooks et al. (2001) who showed that higher concentrations of sulforaphane, a Nrf2 activator, are required to induce NQO1 activity in four human prostate cancer cell lines over normal prostate cells. Tam et al. (2006) has previously demonstrated that increases in lipid, protein and DNA damage due to oxidative stress are prevalent in TRAMP prostate tumors and are reduced upon treatment with N-acetylcysteine. In agreement with this study, we have shown that the oxidative damage in TRAMP may be due to the dysregulation of Nrf2 and subsequent decreases in antioxidant and detoxification proteins. Our data also indicate that Nrf2 downregulation leads to the decreased activity of several GSTs, increased ROS levels and increased DNA damage with tumor progression from normal prostate to primary tumor and metastasis in the TRAMP mouse.
Another model we utilized in this study demonstrated that RbÀ/À prostate epithelial cells are susceptible to carcinogenesis when exposed to increased levels of estrogen (Day et al. 2002) . Estrogens have been implicated in prostate carcinogenesis by several mechanisms such as upregulation of growth factor signaling pathways, an increased expression of antiapoptotic regulators and increased ROS induced DNA damage (reviewed in Ho et al. (2006) ). In addition, Lee et al. (2003a) has demonstrated that catechol estrogen can induce Nrf2 translocation and activation in neuroblastoma and astrocytes in a PI3K-dependant manner. In normal cells, Nrf2 may induce expression of GSTs, which then conjugates catechol estrogen to glutathione. However, as we demonstrate in the Nrf2-deficient RbÀ/À cells, GST expression and activity are significantly diminished when Nrf2 expression is lost. The decrease in catechol detoxification could then lead to an increase in mutagenic DNA adduct formation. Nrf2 has previously been shown to regulate the expression of more classic antioxidant enzymes.
Our results also imply an additional function of Rb in the control of cellular oxidation status. Loss of Rb in both TRAMP and RbÀ/À tissue recombination suggests that Rb function is at least partly responsible for the decrease in Nrf2 and, thus, the increase in ROS and DNA oxidative damage. There is no indication whether Rb directly controls Nrf2 function, however, we have investigated other possible methods of Rb regulation of Nrf2. First, we analysed the effect of transcription factor E2F1, a major target of pRb by both determining Nrf2 expression levels in E2F1 transgenic cell lines and by chromosome immunoprecipitation in RB þ / þ cell lines. The results indicate that E2F1 does not regulate the transcription of Nrf2 (data not shown).
Previously, we have demonstrated that, in an Rb/E2F dependant manner, both TRAMP and RbÀ/À models have increased DNMT1 expression (McCabe et al., 2005a (McCabe et al., , b, 2006 and increased methylation activity. Using methylation specific PCR, we have ruled out Nrf2 promoter methylation. In addition, 5-aza-2-deoxycytidine, a potent DNA methyltransferase inhibitor, treatment did not affect expression of Nrf2 (data not shown).
The TRAMP mouse model disrupts both Rb and p53 (Greenberg et al., 1995) . Our data indicates a greater decrease of Nrf2 expression in TRAMP than in RbÀ/À cell lines indicating potentially cooperative regulation of Nrf2 by both Rb and p53 in TRAMP. Future studies will be required to reveal the molecular mechanism underlying Nrf2 downregulation in RbÀ/À cells and TRAMP tumors.
Increasing attention is being drawn to the role that inflammation plays in prostate carcinogenesis (reviewed in De Marzo et al. (2007) ). De Marzo et al. (2007) discussed several probable causes of prostatic inflammation, such as infectious agents, hormonal changes and dietary habits, which could increase susceptibility to prostate cancer. In support of this, previous studies have also shown that Nrf2 plays an important role in the severity of inflammation. In Nrf2 À/À mice, there is an enhanced inflammatory response to dextran sulfate induced inflammation in colorectal cancer (Osburn et al., 2007) , increased airway inflammation in asthma (Rangasamy et al., 2005) , bacterial endotoxin LPS-induced inflammation (Thimmulappa et al., 2006) and multi-organ autoimmune mediated inflammation and lesions , but the role of Nrf2 in prostatic inflammation is yet to be investigated. As mentioned above, estrogen has been shown to induce tumorigenesis in the RbÀ/À recombination model (Day et al., 2002) , which we have demonstrated has decreased Nrf2 activity. The observations that human cDNA array data obtained from Oncomine indicate that a decrease in Nrf2 mRNA strongly correlates with prostate tumorigenesis, and that Nrf2 knockout mice have shown increased inflammatory response to multiple stimuli provides rationale for further studies of the role Nrf2 plays in the potential role that inflammation plays in the initiation of prostate cancer.
Finally, this study suggests that maintaining or enhancing Nrf2 expression or activation should be explored as a useful chemopreventive strategy for prostate cancer. In addition, it provides further rationale for dietary modifications including antioxidants such as N-acetyl-cysteine and lycopene. In a cellular environment in which Nrf2 is downregulated, antioxidants which negate ROS without the need for phase II detoxification enzymes would be critical as their levels would be decreased. There have been studies in breast, lung and liver, however, which have shown dysregulation Nrf2 by its cytosolic inhibitor Keap1. These studies indicate an increase of Nrf2 levels and Nrf2 regulated gene products. As others have previously shown in the Nrf2 knockout model and we now demonstrate, a loss of Nrf2 expression leads to a predisposition to tumorigenesis. These seemingly contradictory results could be the result of different treatments or different response to hormonal/environmental conditions. This indicates that continued study is needed to provide further insight into Nrf2 regulation, which may prove helpful in elucidating the relationship between persistent oxidative stress and prostate cancer progression.
Materials and methods

Cell culture and treatments
Rb þ / þ and RbÀ/À prostate epithelial cell lines have been previously described (Day et al., 2002) . For these experiments, cells were analysed between passages 20-30. Nrf2 þ / þ and Nrf2À/À mice were kindly provided by Dr Jeffrey Johnson (University of Wisconsin, Madison, WI, USA) and were developed as described previously (Chan et al., 1996) . Cells were analysed between passages 8 and 12. Prostate epithelial cells were derived from these mice as described previously (Day et al., 2002) . The four cell lines were maintained in RPMI 1640 supplemented with 5% fetal bovine serum (Hyclone, Logan, UT, USA), 2 mM L-glutamine and penicillin/streptomycin/Amphotericin B.
Western blot analysis
Rb þ / þ and RbÀ/À cells, and TRAMP tissue lysates were obtained and western blots were performed as described previously (McCabe et al., 2006) . Primary antibodies were as follows: Nrf2 (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), actin (Santa Cruz Biotechnology), pRb (PharMingen, San Diego, CA, USA) and large TAg (PAb416; McCabe et al., 2006) .
Luciferase assay
Cells were plated at 2 Â 10 5 per six-well dish and incubated at 37 1C overnight. Cells were co-transfected with 1 mg of the following promoter-luciferase reporter constructs: NQO1 ARE-Luc (kindly provided by Jeffrey Johnson, University of Wisconsin, Madison, WI, USA). DNA was transfected using Fugene 6 transfection reagent (Rochem, Indianapolis, IN, USA) at a ratio of 3:1 (DNA/Fugene 6) following the manufacturer's protocol. After 48 h of transfection, the cells were treated with tBHQ for 24 h after which whole-cell lysates were collected in lysis buffer. Luciferase expression was determined by adding 50 ml luciferase substrate (Promega, Madison, WI, USA) to 50 ml of lysate, and luciferase activity was monitored using a Monolight 2010 luminometer. b-Galactosidase expression was monitored using a b-galactosidase detection system (Tropix, Bedford, MA, USA) following the manufacturer's protocol using a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA, USA). Statistical analysis was performed on three independent experimental data points and luciferase activity was normalized to b-galactosidase activity. This was then repeated.
RNA isolation and semi-quantitative RT-PCR
Reverse transcription-polymerase chain reaction was performed as described previously (McCabe et al., 2005a, b GST enzymatic assay Total GST enzymatic activity was assayed using the Glutathione S-Transferase Assay kit (Cayman Chemical, Ann Arbor, MI, USA). Lysates were obtained as described previously (McCabe et al., 2006) . The assay was then performed as per instructions. Briefly, an increase in absorbance (340 nm) is measured as 1-chloro-2,4-dinitrobenzene is conjugated to reduced glutathione by GST. The rate of increase in absorbance is directly proportional to GST activity. Statistical analysis was performed on three independent experimental data points and luciferase activity was normalized to b-galactosidase activity. This was then repeated.
DCFDA assay for detection of ROS Assays were performed as described previously (Arnold et al., 2001 ) with modifications. Cells were grown to 60% confluency, washed once, released from the plate with 0.5 ml 0.25% trypsin: 2.7 mM EDTA, and gently pelleted. Cells were resuspended in 2 mM DCFDA in HANKS buffer containing 5% fetal bovine serum and incubated in the dark on a rotating wheel at room temperature for 40 min. Cells were then immediately transferred to ice and analysed on a Becton Dickinson Flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Analysis was performed in triplicate with a Po0.05:(Student's t-test).
Single cell gel electropheris assay DNA damage was assessed using the Comet Assay (Trevigen, Gaithersburg, MD, USA). Cells were harvested by gently scraping with a rubber policeman, washed and resuspended in PBS (Mg þ þ and Ca þ þ free) at 10 5 cells/ml. Suspended cells (50 ml) were mixed with 500 ml of low melting temperature agarose and aliquoted onto a glass slide, and then cooled in the dark for 30 min at 4 1C. The slide was then placed in pre-chilled lysis solution for 30 min at 4 1C followed by alkaline solution, pH>13.0, for 20 min at room temperature in the dark. The cells were electrophoresed at 1 V/cm for 40 min. The slide was rinsed with water, immersed in 70% ethanol for 5 min and allowed to air dry. The DNA was then visualized using SYBER Green I. DNA damage was quantitated by measuring the total DNA area using Image J image software. A minimum of 35 cells were analysed and the experiment was performed in duplicate. The bars indicate the average.
